An overview of cancer treatment modalities

Z Abbas, S Rehman - Neoplasm, 2018‏ - books.google.com
Cancer is a global issue majorly affecting develo** countries. According to a survey, 63%
of deaths due to cancer are reported from develo** countries. There are different …

Protein degradation: expanding the toolbox to restrain cancer drug resistance

H Ming, B Li, J Jiang, S Qin, EC Nice, W He… - Journal of hematology & …, 2023‏ - Springer
Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

Lynch syndrome, molecular mechanisms and variant classification

AB Abildgaard, SV Nielsen, I Bernstein, A Stein… - British journal of …, 2023‏ - nature.com
Patients with the heritable cancer disease, Lynch syndrome, carry germline variants in the
MLH1, MSH2, MSH6 and PMS2 genes, encoding the central components of the DNA …

The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis

X Wang, S **a, H Li, X Wang, C Li, Y Chao… - Cell Death & …, 2020‏ - nature.com
Krüppel-like factor 4 (KLF4), a key transcription factor, acts as a multifunctional player
involved in the progression of numerous aggressive cancers. The proteasome-dependent …

LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization

N Zhang, B Wang, C Ma, J Zeng, T Wang, L Han… - Journal of Experimental …, 2023‏ - Springer
Background Gastric cancer remains the leading cause of cancer death in the world. It is
increasingly evident that long non-coding RNAs (lncRNAs) transcribed from the genome …

Deubiquitylating enzymes in cancer and immunity

J Ren, P Yu, S Liu, R Li, X Niu, Y Chen… - Advanced …, 2023‏ - Wiley Online Library
Deubiquitylating enzymes (DUBs) maintain relative homeostasis of the cellular ubiquitome
by removing the post‐translational modification ubiquitin moiety from substrates. Numerous …

Deubiquitinating enzymes: Promising targets for drug resistance

F Ge, Y Li, T Yuan, Y Wu, Q He, B Yang, H Zhu - Drug Discovery Today, 2022‏ - Elsevier
Highlights•Drug resistance towards chemotherapy and molecularly targeted therapies
remains a great challenge in cancer treatments.•Deubiquitinating enzymes (DUBs) regulate …

Understanding how mismatch repair proteins participate in the repair/anti-recombination decision

U Chakraborty, E Alani - FEMS yeast research, 2016‏ - academic.oup.com
Mismatch repair (MMR) systems correct DNA mismatches that result from DNA polymerase
misincorporation errors. Mismatches also appear in heteroduplex DNA intermediates formed …

Oncogene-induced senescence mediated by c-Myc requires USP10 dependent deubiquitination and stabilization of p14ARF

A Ko, SY Han, CH Choi, H Cho, MS Lee… - Cell Death & …, 2018‏ - nature.com
Oncogene-induced senescence (OIS) is a critical tumor-suppressor mechanism, which
prevents hyper-proliferation and transformation of cells. c-Myc promotes OIS through the …

The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53

C Hu, M Zhang, N Moses, C Hu, L Polin, W Chen… - Cell death & …, 2020‏ - nature.com
Abstract Ubiquitin-specific peptidase 10 (USP10) stabilizes both tumor suppressors and
oncogenes in a context-dependent manner. However, the nature of USP10's role in non …